Fabrazyme 5 mg / 35 mg Powder for solution for infusion
PDF Leaflet Revision Date: 28 October 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of Fabry disease.
Dosage (summary)
1.0 mg/kg body weight IV every 2 weeks over 2 hours.
Special Populations
- Renal insufficiency
- Hepatic insufficiency
- Elderly patients
- Children younger than 8 years
Pregnancy & Breastfeeding
Not recommended during pregnancy; may be excreted in breast milk.
Key Drug Interactions
- Chloroquine
- Amiodarone
- Benoquin
- Gentamycin
Contraindications
- Hypersensitivity to agalsidase beta or excipients
Common side effects
- Headache
- Dizziness
- Nausea
- Vomiting
- Anaphylaxis
Counselling Points
- Monitor for infusion reactions
- Consider home infusion if tolerated
- Avoid during pregnancy and breastfeeding
Serious warnings
- Infusion-associated reactions
- Hypersensitivity reactions
Important Disclaimer
The Fabrazyme 5 mg / 35 mg Powder for solution for infusion professional information leaflet below is the property of Sanofi-Aventis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
